PPAR Agonists for the Prevention and Treatment of Lung Cancer
Lung cancer is the most common and most fatal of all malignancies worldwide. Furthermore, with more than half of all lung cancer patients presenting with distant metastases at the time of initial diagnosis, the overall prognosis for the disease is poor. There is thus a desperate need for new prevent...
Saved in:
Main Authors: | Sowmya P. Lakshmi, Aravind T. Reddy, Asoka Banno, Raju C. Reddy |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2017/8252796 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PPARγ as a Novel Therapeutic Target in Lung Cancer
by: Aravind T. Reddy, et al.
Published: (2016-01-01) -
PPARγ in Bacterial Infections: A Friend or Foe?
by: Aravind T. Reddy, et al.
Published: (2016-01-01) -
PPAR Agonists and Cardiovascular Disease in Diabetes
by: Anna C. Calkin, et al.
Published: (2008-01-01) -
PPARs in Alveolar Macrophage Biology
by: Monica R. Smith, et al.
Published: (2007-01-01) -
New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
by: Zhanjun Jia, et al.
Published: (2014-01-01)